ArticleThe Lancet. Infectious diseases2023

Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.

Daniel Jenkin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.